By Adriano Marchese
Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors.
Shares traded 55% lower ahead of the morning bell at $3.51.
The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board.
The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause.
The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being.
Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory authorities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 10, 2025 06:28 ET (11:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.